Participate in Research
Post-Psychedelic Challenges Study
A study to understand the nature of post-psychedelic challenges.
Who is eligible?
We are seeking anyone who has experienced difficulties, challenges, or distress related to psychedelics. To be eligible to participate, you must also be 18 years old or older, be able to read and understand English, and to reside in the United States or Canada.
What does participation look like?
- After filling out the short online screener questionnaire, we will invite participants who may be eligible to a 10-minute zoom conversation for screening purposes. This screening will not be recorded. If eligible, we will share the study consent form with you, and you will have an opportunity to ask any questions you have about the study. The consent form outlines important details to know about the study.
- Once you have consented to participate, we will share an online questionnaire with you. The questionnaire is comprehensive because we are interested in the details of your experience. It takes approximately 1-2 hours to complete, and you can take breaks at any point.
- After taking the survey, participants will be asked to provide any email through which they can receive a $30.00 gift card as compensation for participating.
Learn more about participating
MDMA PTSD Study
Principal Investigator Jessica Maples-Keller, PhD is recruiting for a study on MDMA + prolonged exposure therapy as treatment for PTSD. If you have a PTSD diagnosis, you may be eligible to enroll this study. Study participants will receive monetary compensation, and all involvement will be kept confidential.
Study inclusion criteria:
- Must be 21-70 years old
- Must complete a psychiatric and medical history screening
- Must have ability to read and understand the English language
This study will require multiple visits for the following:
- Screening visits
- Physical exam
- Minimum of 10 Prolonged Exposure sessions over the course of 2-weeks
- Single dose of MDMA
- Completion of questionnaires
- 3 virtual follow-up visits
Study Location:
Emory University Brain Health Center at Executive Park 12
Click here to submit an interest form
Emory Mood & Anxiety Disorders Program Studies
The Emory Mood and Anxiety Disorders Program (MAP) is currently conducting several studies in adults focusing on the use of psychedelics, combined with psychological support, as a potential new, effective, and safe treatment for Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD). The study durations range from 16 weeks to one year.
All study participants will receive a psychiatric evaluation, physical exam, and laboratory tests at no cost. Please read throught the brief study descriptions on this page.
If you are interested in participating, contact us directly at 404-778-MOOD (6663) or study@emory.edu. In your message please include your name, age, and the study you are interested in. We will contact you as soon as possible.
Emory MAP Psychedelics Study Descriptions
This nation-wide study is evaluating the safety and efficacy of a synthetic form of psilocybin for patients suffering from treatment-resistant depression (TRD). Participants will receive a single dose of psilocybin or placebo, in combination with psychological support. Participants must have previously tried antidepressants and experienced little relief from their depression symptoms.
This study, conducted globally, is investigating the efficacy and safety of three different dosages of a synthetic psychedelic nasal spray for patients with treatment-resistant depression (TRD). In addition to a single dose of the compound, participants will receive psychological support. Participants must have previously tried antidepressants with little relief from their depression symptoms.
This global study is evaluating the safety and efficacy of a synthetic form of psilocybin for patients currently suffering of major depressive disorder (MDD) with at least moderate symptom severity. Participants will receive a single dose of psilocybin (25mg or 5 mg), or placebo, in combination with psychosocial support.
This study, conducted nation-wide, is evaluating the safety and efficacy of RE104, a synthetic psychedelic, for adult female patients with postpartum depressive disorder. Participants will receive a single dose of the compound (30mg or 1.5 mg) in combination with psychosocial support.